OSA

Question 1

Turner
OSA prognosis
JAVMA 2017

Answer 1

No tx for metastasis
MST 49d

Metastasectomy alone
MST 232d

No affect
preceding DFI

Question 2

Sabattini
Cytology vs History for Bone Lesions
JVIM 2017

Answer 2

Accuracy
50% cytology
56% Histo

Question 3

Leeper
Cholesterol Concentrations in OSA
JSAP 2017

Answer 3

Elevated total cholesterol
45% OSA dogs
10% fracture control

associated with a reduced hazard ratio for overall mortality in dogs with osteosarcoma

Question 4

Turner, JAVMA, 2017:
Stage III OSA
How did metastasectomy affect MST?
In what situation(s) did pulmonary metastasectomy provide a survival advantage?
What tumor location was associated with a shorter DFI and overall survival time?

Answer 4

Turner, JAVMA, 2017:
Metastasectomy was associated with a longer MST
Pulmonary metastasectomy offered a survival advantage if there were <3 nodules on thoracic radiography and a DFI of >275 days, but not if there was metastasis to viscera other than lungs
Tumor location in the proximal humerus was associated with a shorter DFI and overall survival time

Question 5

Matsuyama, JAVMA, 2018:
Limb amputation + carboplatin chemotherapy + metronomic cyclophosphamide chemotherapy for appendicular OSA
What did 58% of the dogs that received metronomic cyclophosphamide chemotherapy develop?
What effect did metronomic cyclophosphamide chemotherapy have on median DFI and overall survival time?

Answer 5

Matsuyama, JAVMA, 2018:
58% developed cystitis
No effect on median DFI or overall survival time

Question 6

Santamaria, JAVMA, 2019:
Limb amputation + single subcutaneous infusion of carboplatin for appendicular OSA
MST?
DFI?
What adverse effect(s) of chemotherapy did 7% of the dogs develop?
Any benefit over limb amputation alone?

Answer 6

Santamaria, JAVMA, 2019:
MST 196 days
DFI 197 days
GI signs in 7% of the dogs
No benefit in MST over limb amputation alone

Question 7

Parachini-Winter, JVIM, 2019:
Cutaneous and subcutaneous metastasis of appendicular OSA
What % had incidental finding of cutaneous and subcutaneous metastasis?
What % developed pulmonary metastasis and what % developed bone metastasis?
Median cutaneous and subcutaneous metastasis-free interval?
Median cutaneous and subcutaneous metastasis survival time?
Prognosis after diagnosis of cutaneous and subcutaneous metastasis?

Answer 7

Parachini-Winter, JVIM, 2019:
95% incidental finding of cutaneous and subcutaneous metastasis
85% developed pulmonary metastasis and 5% developed bone metastasis
Median CSM-free interval: 160 days
Median CSM survival time: 55 days
Grave prognosis

Question 8

Giuffrida, Vet Surg, 2018:
Primary appendicular HSA vs telangiectatic OSA (tOSA)
Distribution of HSA vs tOSA?
Risk factor(s) for tOSA?
Which tumor is more likely to cause lameness and which tumor is more likely to cause limb swelling?
Rate of pulmonary metastasis for HSA vs tOSA?
Overall survival time for tOSA treated with local treatment + chemo vs local treatment alone vs no treatment?
Overall survival time for HSA treated with local treatment + chemo vs local treatment alone?
More aggressive treatment with associated with longer survival time in dogs with which tumor?

Answer 8

Giuffrida, Vet Surg, 2018:
HSA: 78% in the hindlimbs - proximal tibia > mid-tibia > proximal femur
tOSA: 83% in the forelimbs - proximal humerus > distal radius
Odds of tOSA increased 1.6-fold for each 5kg increase in body weight
HSA was more likely to cause lameness but tOSA was more likely to cause limb swelling
Pulmonary metastasis: 20% of HSA vs 7% of tOSA
Overall survival times for tOSA: 7 months for local treatment + chemo vs 4.5 months for local treatment alone vs 3 months for no treatment
Overall survival times for HSA: 10 months for local treatment + chemo vs 3.5 months for local treatment alone
More aggressive treatment was associated with longer survival in dogs with HSA but not tOSA